Implementation of reperfusion therapy in acute myocardial infarction. A policy statement from the European Society of Cardiology

被引:124
|
作者
Bassand, JP [1 ]
Danchin, N [1 ]
Filippatos, G [1 ]
Gitt, A [1 ]
Hamm, C [1 ]
Silber, S [1 ]
Tubaro, M [1 ]
Weidinger, F [1 ]
机构
[1] Univ Hosp Jean Minjoz, Dept Cardiol, F-2500 Besancon, France
关键词
myocardial infarction; reperfusion therapy; primary PCI;
D O I
10.1093/eurheartj/ehi673
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Reperfusion therapy in ST-segment elevation myocardial infarction (STEMI) is the most important component of treatment, as it strongly influences short- and long-term patient outcome. The main objective of healthcare providers should be to achieve at least 75% of reperfusion therapy applied to patients suffering from STEMI in a timely manner, and preferably within the first 3 h after onset of symptoms. Establishing networks of reperfusion at regional and national level, implying close collaboration between all the actors involved in reperfusion therapy, namely hospitals, departments of cardiology, PCI centres, emergency medical systems (EMS), (para)medically staffed ambulances, private cardiologists, primary care physicians, etc., is a key issue. All forms of reperfusion, depending on local facilities, need to be available to patients. Protocols must be written and agreed for the strategy of reperfusion to be applied within a network. Early diagnosis of STEMI is essential and is best achieved by rapid ECG recording and interpretation at first medical contact, wherever this contact takes place (hospital or ambulance). Tele-transmission of ECG for immediate interpretation by experienced cardiologists is an alternative. Primary PCI is the preferred reperfusion option if it can be performed by experienced staff within 90 min after first medical contact. Thrombolytic treatment, administered if possible in the pre-hospital setting, is a valid option if PCI cannot be performed in a timely manner, particularly within the first 3 h following onset of symptoms. Thrombolysis is not the end of the reperfusion therapy. Rescue PCI must be performed in the case of thrombolysis failure. Next-day PCI after successful thrombolysis has been proven efficacious. Quality control is important for monitoring the efficacy of networks of reperfusion. All elements that influence time to reperfusion must be taken into account, particularly transfer delays, in-hospital delays, and door-to-balloon or door-to-needle times. The rate of reperfusion achieved must also be taken into consideration. Professional organizations such as the European Society of Cardiology (ESC) have the responsibility to impart this message to the cardiology community, and inform politicians and health authorities about the best possible strategy to achieve reperfusion therapy.
引用
收藏
页码:2733 / 2741
页数:9
相关论文
共 50 条
  • [1] Perspective: Reperfusion therapy in acute myocardial infarction.
    Lange, RA
    Hillis, LD
    NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (13): : 954 - 955
  • [2] A predictive instrument for reperfusion therapy for acute myocardial infarction.
    Kent, DM
    Ruthazer, R
    Beshansky, JR
    Griffith, JL
    Grines, CL
    Aversano, T
    Zalenski, R
    Selker, HP
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2003, 18 : 225 - 225
  • [3] Implementation of reperfusion therapy in ST-segment elevation myocardial infarction A policy statement from the Belgian Society of Cardiology (BSC), the Belgian Interdisciplinary Working Group on Acute Cardiology (BIWAC) and the Belgian Working Group on Interventional Cardiology (BWGIC)
    Claeys, Marc J.
    Gevaert, Sofie
    De Meester, Antoine
    Evrard, Patrick
    Legrand, Victor
    Vrints, Chris
    Berkenboom, Guy
    Desmet, Walter
    Van Langenhove, Glenn
    Vranckx, Pascal
    De Raedt, Herbert
    Van de Werf, Frans
    Van den Branden, Frank
    ACTA CARDIOLOGICA, 2009, 64 (04) : 541 - 545
  • [4] Complications of immediate reperfusion therapy during acute myocardial infarction.
    Noga, CM
    Stewart, RE
    Ratliff, NB
    LABORATORY INVESTIGATION, 1999, 79 (01) : 38A - 38A
  • [5] Participation in thrombolytic trials delays reperfusion therapy in acute myocardial infarction.
    Wasek, WC
    Stec, S
    Mazurek, T
    Budaj, A
    Klosiewicz-Wasek, B
    Maciejewski, P
    Bednarz, B
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (03) : 194A - 194A
  • [6] Effects of intravenous magnesium therapy on ischemia/reperfusion injury in acute myocardial infarction.
    Yang, P
    Steurer, G
    Smetana, R
    MAGNESIUM-BULLETIN, 1996, 18 (04): : 104 - 106
  • [7] Usefulness of reperfusion therapy with a distal protection device (percusurge) for acute myocardial infarction.
    Ito, Y
    Muramatsu, T
    Tsukahara, R
    Ho, M
    Hirano, K
    Nakano, M
    Matsushita, M
    AMERICAN JOURNAL OF CARDIOLOGY, 2002, 90 (6A): : 184H - 184H
  • [8] Reperfusion in acute myocardial infarction. Thrombolysis or balloon dilatation?
    Zeymer, U
    Neuhaus, KL
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1997, 122 (36) : 1081 - 1085
  • [9] Time to reperfusion in acute myocardial infarction. It is time to reduce it!
    Barbagelata, Alejandro
    Perna, Eduardo R.
    Clemmensen, Peter
    Uretsky, Barry F.
    Canella, Juan P. Cimbaro
    Califf, Robert M.
    Granger, Christopher B.
    Adams, George L.
    Merla, Ramanna
    Birnbaum, Yochai
    JOURNAL OF ELECTROCARDIOLOGY, 2007, 40 (03) : 257 - 264
  • [10] Acute Myocardial Infarction Complicated by Cardiogenic Shock: Analysis of the Position Statement From the European Society of Cardiology Acute Cardiovascular Care Association, With Perioperative Implications
    Cormican, Daniel S.
    Sonny, Abraham
    Crowley, Jerome
    Sheu, Richard
    Sun, Terri
    Gibson, Christina M.
    Nunez-Gil, Ivan J.
    Ramakrishna, Harish
    JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2021, 35 (10) : 3098 - 3104